|
Acute alcoholic liver disease
|
0.200 |
Therapeutic
|
disease |
RGD |
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
|
27939985 |
2017 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Lipid levels and body mass index values strongly correlated with FGF19 and FGFR4 levels in patients with colon adenomas.
|
30517925 |
2019 |
|
Adenoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
These observations indicate that the FGF19/FGFR4 pathway may be involved in the development of neoplasia, and that FGF19 may be a valuable diagnostic marker for the identification of patients with colorectal adenomas.
|
30517925 |
2019 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In 18 evaluable patients with FGFR genetic alterations, 3 confirmed partial responses (two intrahepatic cholangiocarcinomas (iCCA) with FGFR2 fusions and one urothelial cancer with FGFR2 and FGF19 amplification) and two durable stable disease at ⩾16 weeks with tumour reduction (FGFR2 fusion-positive iCCA and adrenocortical carcinoma with FGFR1 amplification) were observed.
|
28972963 |
2017 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.
|
21397858 |
2011 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that FGFR4 expression is markedly increased in high-grade PanIN and PDAC compared with that in normal and low-grade PanIN, and that FGFR4 stimulation by FGF19 of PDAC cells contributes to tumor suppression by increasing cell adhesion to extracellular matrix.
|
21109934 |
2011 |
|
Apert syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further research is needed to determine the role of modulation of MSC proliferation or use of FGF19 or anti-BMP2 as inhibitors of osteogenesis in AS subjects' cells, and whether these findings can be used in the clinical management of AS.
|
27339175 |
2016 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
|
30679232 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
|
30679232 |
2019 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.
|
28507750 |
2017 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
FGF19 profiles in PBAD patients included low fasting and meal-stimulated responses, which were both strongly correlated with SeHCAT.
|
26856750 |
2016 |
|
Bile acid diarrhea
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Our finding that <sup>19</sup>F MRI differentiates FGF15-deficient from WT mice provides additional proof-of-concept for the development of <sup>19</sup>F bile acid analogues and <sup>19</sup>F MRI as a clinical test to diagnose bile acid diarrhea due to FGF19 deficiency and other disorders.
|
30247920 |
2018 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
To explore if an impaired FGF19 response identifies primary bile acid diarrhoea.
|
28378364 |
2017 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
Metformin use was an important factor in a subgroup, lowering FGF19, and resulting in bile acid diarrhea.
|
30682184 |
2019 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
With replicate tests in patients with stable IBS-D, 78% of C4 and 70% of FGF19 measurements remained concordant, with 3% and 11% respectively consistently positive for bile acid diarrhoea in the 101 patients.
|
28691284 |
2017 |
|
Bile acid diarrhea
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Patients with bile acid diarrhea (BAD) are identified based on increased levels of BAs in fecal samples collected over a 48-hr period while on a 100-gram fat diet (48-hr BA), retention of <sup>75</sup>Se-labeled homocholic acid taurine, or serum levels of C4 or FGF19.
|
29902647 |
2019 |
|
Bile acid malabsorption
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed area under the receiver operating characteristic curve (AUROC) analysis to identify the optimal cutoff C4 concentrations for the diagnosis of diarrhea attributable to bile acid malabsorption (BAD), defined as diarrhea and a serum concentration of FGF19 <60 pg/mL.
|
30448597 |
2019 |
|
Biliary Atresia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The FGF19 protein was synthesized in BA HET, and its serum concentration was elevated.
|
30156739 |
2019 |
|
Brachial Amyotrophic Diplegia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bile acid sequestrants are the primary treatments for BAD; the farnesoid X-receptor-FGF-19 pathway provides alternative therapeutic targets for BAD.
|
28169840 |
2017 |
|
Brachial Amyotrophic Diplegia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Median serum FGF19 on conventional sequestrant treatment was 28% lower than baseline values in BAD (<i>p</i> < 0.05).
|
28507750 |
2017 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The CCND1-FGF19-FGF4-FGF3 gene cluster in human chromosome 11q13 is amplified in breast cancer, squamous cell carcinoma of head and neck, and bladder tumors, and is also translocated in parathyroid tumors and B-cell lymphoma.
|
12429977 |
2002 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overall, these insights support the idea that targeting FGFR4 in breast cancer cells overexpressing FGF19 may represent an effective strategy to suppress cancer development, progression, and metastasis.
|
30074276 |
2018 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood.
|
28906590 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
However, FGF19 has also been implicated in hepatocellular carcinogenesis, and consequently, the potential risk from prolonged exposure to supraphysiological levels of the hormone represents a major hurdle for developing an FGF19-based therapy.
|
25080475 |
2014 |